Back to discover
Disease

multiple endocrine neoplasia type 2A

Clinical development underway
Also known as MEA type 2a, MEA type II, MEN2A, RET-related multiple endocrine neoplasia type 2A+19 more

MEA type 2a, MEA type II, MEN2A, RET-related multiple endocrine neoplasia type 2A, Sipple syndrome, men 2A, men type 2a, men type II, multiple endocrine adenomatosis type 2A, multiple endocrine adenomatosis type 2a, multiple endocrine adenomatosis type II, multiple endocrine adenomatosis, type II, multiple endocrine neoplasia II, multiple endocrine neoplasia IIA, multiple endocrine neoplasia type II, multiple endocrine neoplasia, type II, ptc syndrome, men-2A syndrome, multiple endocrine neoplasia, type 2A, multiple endocrine neoplasia, type IIA, pheochromocytoma and amyloid producing medullary thyroid carcinoma, pheochromocytoma and amyloid-producing medullary thyroid carcinoma, thyroid carcinoma, familial medullary.

3
Clinical trials
1
Associated genes
1
Related proteins

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

No activity recorded in this window. Try a wider timeframe.

Clinical trials

2 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
3
All trials
0
Active
0
Late-stage
2
Completed

Associated genes

1 match

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

Disease biology

1 match

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A form of multiple endocrine neoplasia characterized by the presence of medullary carcinoma (CARCINOMA, MEDULLARY) of the THYROID GLAND, and usually with the co-occurrence of PHEOCHROMOCYTOMA, producing CALCITONIN and ADRENALINE, respectively. Less frequently, it can occur with hyperplasia or adenoma of the PARATHYROID GLANDS. This disease is due to gain-of-function mutations of the MEN2 gene on CHROMOSOME 10 (Locus: 10q11.2), also known as the RET proto-oncogene that encodes a RECEPTOR PROTEIN-TYROSINE KINASE. It is an autosomal dominant inherited disease.

Synonyms

MEA type 2a, MEA type II, MEN2A, RET-related multiple endocrine neoplasia type 2A, Sipple syndrome, men 2A, men type 2a, men type II, multiple endocrine adenomatosis type 2A, multiple endocrine adenomatosis type 2a, multiple endocrine adenomatosis type II, multiple endocrine adenomatosis, type II, multiple endocrine neoplasia II, multiple endocrine neoplasia IIA, multiple endocrine neoplasia type II, multiple endocrine neoplasia, type II, ptc syndrome, men-2A syndrome, multiple endocrine neoplasia, type 2A, multiple endocrine neoplasia, type IIA, pheochromocytoma and amyloid producing medullary thyroid carcinoma, pheochromocytoma and amyloid-producing medullary thyroid carcinoma, thyroid carcinoma, familial medullary

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.